| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1033 | |
| Phytochemical name or plant extracts | Lentinula edodes mycelia extract | |
| PMID | 23874107 | |
| Literature evidence | Concomitant use of LEM(Lentinula edodes mycelia extract) with FEC75 therapy can maintain host QOL and immune function, and offer important implications for an application of LEM as a useful oral adjuvant to anthracycline-based chemotherapies. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Mycelia extract | |
| Source of phytochemicals or plant Extracts | Lentinula edodes | |
| Geographical availability | East Asia(mainly in China and Japan) | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | SOD1 | |
| Gene or Protein evidence | Immunohistochemical assessment of SOD1 as markers of inflammation and oxidative stress were performed. | |
| Target pathways | TLR4/Dectin1-MAPK and Syk-PKC-NF-κB pathways | |
| IC50 | NA | |
| Potency | Subjects were treated with two courses of FEC75 chemotherapy (5-fluorouracil [5-FU], 500 mg/m2, cyclophosphamide, 500 mg/m2, epirubicin, 75 mg/m2) for 3 weeks as one course. The first course comprised FEC75 chemotherapy alone, whereas the second course used LEM in combination with FEC. In the second course, subjects took 1800 mg/day of LEM every day for the 3 weeks. | |
| Cell line/ mice model | MCF-7 and MDA-MB-231 cells. | |
| Additional information | Latcripin-7a, derivative of Lentinula edodes c(91-3), reduces migration and induces apoptosis, autophagy, and cell cycle arrest at G-(1) phase in breast cancer cells. | |
| PubChem ID | NA | |
| Additional PMIDs | 19020765 33044599 | |
| Additional sources of information | http://bioweb.uwlax.edu/bio203/s2007/hendzel_abby/Habitat.htm#:~:text=Lentinula%20edodes%20is%20native%20to,of%20the%20mushroom's%20life... | |
| Safety | NA |